Triamcinolone Acetonide (Azmacort)

An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.

Also Known As:

Networked: 1718 relevant articles (282 outcomes, 258 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Jonas, Jost B: 43 articles (01/2013 - 09/2002)
2.	Sakamoto, Taiji: 22 articles (06/2014 - 02/2003)
3.	Jonas, J B: 22 articles (03/2007 - 09/2000)
4.	Kreissig, Ingrid: 18 articles (01/2009 - 09/2002)
5.	Scott, Ingrid U: 14 articles (09/2015 - 10/2003)
6.	Degenring, Robert F: 14 articles (08/2006 - 09/2002)
7.	Kreissig, I: 12 articles (01/2006 - 01/2003)
8.	Ozdemir, Hakan: 11 articles (01/2013 - 03/2004)
9.	Gillies, Mark C: 11 articles (01/2013 - 05/2003)
10.	Karacorlu, Murat: 11 articles (01/2013 - 03/2004)

Related Diseases

1.	Macular Edema 07/01/2004 - "This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema." 05/01/2008 - ": To determine safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for refractory clinically significant diabetic macular edema (DME). " 05/01/2005 - "A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity." 03/01/2010 - "Intravitreal triamcinolone acetonide showed to be effective for improving visual acuity in patients with diabetic macular edema, in the first three months of treatment. " 08/01/2005 - "Intravitreal triamcinolone acetonide is an effective treatment for serous macular detachment in patients with diabetic macular edema."
2.	Macular Degeneration (Age-Related Maculopathy) 06/01/2001 - "Animal models, in vitro assays and pilot clinical studies suggest that intravitreal triamcinolone acetonide may be useful in the treatment of age-related macular degeneration. " 09/01/2000 - "Whilst animal studies and a pilot clinical trial suggest that intravitreal triamcinolone acetonide (TA) may be useful in the treatment of age-related macular degeneration (AMD), its mode of action remains to be fully elucidated. " 01/01/2006 - "To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). " 01/01/2000 - "Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. " 01/01/2012 - "To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. "
3.	Retinal Vein Occlusion 01/01/2008 - "To assess the long-term safety and efficacy of intravitreal triamcinolone acetonide injection in the management of macular oedema caused by central, hemi-, and branch retinal vein occlusion (CRVO, HRVO, or BRVO). " 11/01/2008 - "This study demonstrates a benefit associated with intravitreal triamcinolone acetonide injection for retinal vein occlusions that was maintained by patients with branch retinal vein occlusions and hemiretinal vein occlusions over a 12-month period. " 01/01/2008 - "The aim of the study was to evaluate the safety and effectiveness of trans-Tenon's retrobulbar triamcinolone acetonide (TA) injection for macular oedema associated with branch retinal vein occlusion (BRVO). " 10/01/2012 - "Intravitreal triamcinolone acetonide may improve macular sensitivity and morphology in patients with ischemic and nonischemic branch retinal vein occlusion." 02/01/2011 - "Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion."
4.	Pain (Aches) 06/03/2015 - "The 40-mg dose of FX006 produced pain relief that was improved at two through twelve weeks and was significantly superior to immediate-release triamcinolone acetonide at five to ten weeks (p < 0.05 at each time point). " 06/03/2015 - "The 10-mg dose of FX006 produced pain relief that was improved relative to immediate-release triamcinolone acetonide at two through twelve weeks, although the difference in pain relief was not significant (p ≥ 0.05). " 04/20/2009 - "SIJ blocks with triamcinolone acetonide are beneficial for some patients with SIJ pain without spondyloarthropathy. " 06/03/2015 - "The present study was undertaken to determine if FX006, an extended-release formulation of triamcinolone acetonide, can provide pain relief that is superior to the current standard of care, immediate-release triamcinolone acetonide. " 04/20/2009 - "The study aimed to investigate the therapeutic efficacy of sacroiliac joint (SIJ) blocks with triamcinolone acetonide in patients with SIJ pain without spondyloarthropathy. "
5.	Inflammation 11/01/2013 - "Intracameral triamcinolone acetonide was highly effective in controlling postoperative inflammation in phacotrabeculectomy, and triamcinolone acetonide 1.0 mg provided the best postoperative result. " 11/01/2013 - "Intracameral injection of triamcinolone acetonide in phacotrabeculectomy resulted in a significant reduction in aqueous inflammation and improvement in visual acuity." 05/01/2008 - "Intravitreal triamcinolone acetonide is effective in treating various ocular disorders associated with inflammation and swelling of the retina. " 04/01/2012 - "Supratarsal injection of triamcinolone acetonide is effective and safe in patients with severe chronic allergic keratoconjunctivits to relieve severe inflammation associated with this disease." 07/01/2006 - "Posterior subtenon injection of triamcinolone acetonide proved to be a safe and effective way of treating intraocular inflammations."

Related Drugs and Biologics

1.	bevacizumab
2.	Retinaldehyde (Retinal)
3.	1-phenyl-3,3-dimethyltriazene (PDT)
4.	Triamcinolone Acetonide (Azmacort)
5.	verteporfin (Visudyne)
6.	fluticasone (Cutivate)
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	Beclomethasone (Beclometasone)
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
10.	canakinumab

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Vitrectomy
3.	Lasers (Laser)
4.	Light Coagulation
5.	Injections